Chief Science Officer of $SES sells 150,000 shares in insider sale

The Chief Science Officer of $SES, Hong Gan, recently sold 150,000 shares of the company on January 22, 2026, for an estimated $374,384. This transaction, representing approximately 10.7% of their shares of this class of stock, was disclosed in a recent SEC filing. Following this sale, Gan now holds 1,253,286 shares of this class of $SES stock.

In the past six months, $SES insiders have engaged in trading activities on the open market four times. Of these trades, none were purchases, and all four were sales. Specifically, Hong Gan, the Chief Science Officer, has made no purchases and four sales, selling a total of 500,000 shares for an estimated $1,107,820.

Furthermore, institutional investors have made significant moves with respect to $SES stock in their portfolios. 49 institutional investors have added shares of $SES, while 61 have decreased their positions in the most recent quarter. Some of the largest recent movements include Temasek Holdings (Private) Ltd removing 15,393,562 shares (-54.8%) from their portfolio, Citadel Advisors LLC adding 3,832,786 shares (+1457.6%), Millennium Management LLC adding 2,519,665 shares (+132.2%), Vanguard Group Inc adding 1,927,945 shares (+21.1%), Blackrock, Inc. adding 1,658,299 shares (+58.4%), Geode Capital Management, LLC adding 1,237,105 shares (+70.5%), and Two Sigma Investments, LP adding 1,223,673 shares (+183.3%).

Analysts have recently issued price targets for $SES, with a median target price of $17.0. Konark Gupta from Scotiabank set a target price of $20.0 on January 21, 2026, Derek Soderberg from Cantor Fitzgerald set a target price of $4.0 on November 6, 2025, and Arthur Nagorny from RBC Capital set a target price of $17.0 on July 30, 2025.

It is essential to note that this article does not constitute financial advice. For more information, refer to Quiver Quantitative’s disclaimers.